Praziquantel as the preferred treatment for schistosomiasis

Int Marit Health. 2024;75(1):49-54. doi: 10.5603/imh.99453.

Abstract

Schistosomiasis, caused by Schistosoma trematode worms, represents a significant global health challenge. This review offers a thorough examination of the disease's epidemiology, transmission dynamics, diagnostic modalities, and treatment options. Diagnostic techniques encompass direct parasitological methods, immunological assays, DNA/RNA detection, and biomarker utilization, each with distinct advantages and limitations. There is an urgent need for improved diagnostic tools with enhanced sensitivity and specificity. Praziquantel remains the cornerstone of treatment, exhibiting efficacy against all Schistosoma species, while the potential of artemisin derivatives in combination therapy is also explored. In this review, we focus on the importance of praziquantel administration as the central aspect of schistosomiasis treatment, highlighting ongoing efforts to optimize its utilization for improved patient outcomes.

Keywords: praziquantel; schistosome; schistosomiasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Anthelmintics* / therapeutic use
  • Humans
  • Praziquantel* / therapeutic use
  • Schistosoma / drug effects
  • Schistosomiasis* / diagnosis
  • Schistosomiasis* / drug therapy

Substances

  • Praziquantel
  • Anthelmintics